AstraZeneca Bounds Into A Chase Zone As Cancer Drugs Drive Sales Beat

Core Insights - AstraZeneca reported earnings of $2.38 per share and $15.19 billion in third-quarter sales, exceeding analyst expectations of $2.29 per share and $14.78 billion in sales [1][2] - Revenue from cancer drugs increased by 19% to $6.64 billion, making up 44% of total sales for the quarter [1] - The company reiterated its guidance, expecting core earnings to rise by a low double-digit percentage and sales to increase by a high single-digit percentage [2] Financial Performance - In the same period last year, AstraZeneca earned $2.08 per share with $13.57 billion in sales [2] - The stock rose by 3.1% to $83.63 in premarket trading following the earnings report [2] Market Position - Analysts project AstraZeneca's earnings for the year to be $9.14 per share with total sales of $58.17 billion [2]